A Study for Participants With Pancreatic Cancer

Phase 1/2 Completed 157 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether LY2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment for participants with pancreatic cancer.

Timeline

Start: 2009-02
Primary completion: 2013-02
Completion: 2013-12

Publications

Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 2017 Feb 15;17(1):137. doi: 10.1186/s12885-017-3131-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	RABUSERTIB	Small molecule	70 mg/m2	Intravenous
Subject	RABUSERTIB	Small molecule	105 mg/m2	Intravenous
Subject	RABUSERTIB	Small molecule	150 mg/m2	Intravenous
Subject	RABUSERTIB	Small molecule	200 mg/m2	Intravenous
Subject	RABUSERTIB	Small molecule	200 mg	Intravenous
Subject	RABUSERTIB	Small molecule	230 mg	Intravenous
Subject	RABUSERTIB	Small molecule	250 mg/m2	Intravenous

A Study for Participants With Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications